-
Send to Friends (0)
Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Checklist of Responsibilities for the Scientific Editor of This Article
Publishing Process of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (4136)
All Articles published online
|
Publishing Process of This Article
|
Jun 14, 2021 (publication date) through May 31, 2023
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Zhang Y, Huang ZX, Song B. Role of imaging in evaluating the response after neoadjuvant treatment for pancreatic ductal adenocarcinoma. World J Gastroenterol 2021; 27(22): 3037-3049 [PMID: 34168406 DOI: 10.3748/wjg.v27.i22.3037] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v27/i22/3037.htm |
| Number | Citing Articles |
| 1 |
Victor Hugo Fonseca de Jesus, Rachel P. Riechelmann. Current Treatment of Potentially Resectable Pancreatic Ductal Adenocarcinoma: A Medical Oncologist’s Perspective. Cancer Control 2023; 30: 107327482311732 doi: 10.1177/10732748231173212
|
| 2 |
Madeline T. Olson, Eric N. Aguilar, Cory L. Brooks, Carly C. Isder, Kathryn M. Muilenburg, Geoffrey A. Talmon, Quan P. Ly, Mark A. Carlson, Michael A. Hollingsworth, Aaron M. Mohs. Preclinical Evaluation of a Humanized, Near-Infrared Fluorescent Antibody for Fluorescence-Guided Surgery of MUC16-Expressing Pancreatic Cancer. Molecular Pharmaceutics 2022; 19(10): 3586 doi: 10.1021/acs.molpharmaceut.2c00203
|
| 3 |
Tomoyuki Kawada. Prognostic factors in patients with pancreatic ductal adenocarcinoma with neoadjuvant treatment and pancreatectomy. Journal of Surgical Oncology 2022; 125(6): 1071 doi: 10.1002/jso.26819
|
| 4 |
Luis Secanella, Juli Busquets, Núria Peláez, María Sorribas, Berta Laquente, Sandra Ruiz, Thiago Carnaval, Sebastián Videla, Juan Fabregat. Predictive factors for resection and survival in type A borderline resectable pancreatic ductal adenocarcinoma patients after neoadjuvant therapy: A retrospective cohort study. Medicine 2022; 101(48): e32126 doi: 10.1097/MD.0000000000032126
|
| 5 |
Chao Qu, Piao‐e Zeng, Hang‐yan Wang, Chun‐hui Yuan, Hui‐shu Yuan, Dian‐rong Xiu. Application of Magnetic Resonance Imaging in Neoadjuvant Treatment of Pancreatic Ductal Adenocarcinoma. Journal of Magnetic Resonance Imaging 2022; 55(6): 1625 doi: 10.1002/jmri.28096
|
| 6 |
Yun Bian, Hui Jiang, Jianming Zheng, Chengwei Shao, Jianping Lu. Basic pancreatic lesions: Radiologic-pathologic correlation. Journal of Translational Internal Medicine 2022; 10(1): 18 doi: 10.2478/jtim-2022-0003
|
| 7 |
Wenke Yin, Xiaoyan Song, Yue Xiang. WDR79 promotes aerobic glycolysis of pancreatic ductal adenocarcinoma (PDAC) by the suppression of SIRT4. Open Medicine 2023; 18(1) doi: 10.1515/med-2022-0624
|
| 8 |
Amanda Puleo, Midhun Malla, Brian A. Boone. Defining the Optimal Duration of Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma. Pancreas 2022; 51(9): 1083 doi: 10.1097/MPA.0000000000002147
|